Early Antiretroviral Therapy for HIV-Infected Adults with Tuberculosis
Author Information
Author(s): Molly F. Franke, James M. Robins, Jules Mugabo, Felix Kaigamba, Lauren E. Cain, Julia G. Fleming, Megan B. Murray
Primary Institution: Harvard School of Public Health
Hypothesis
Does early initiation of combination antiretroviral therapy (cART) improve survival among HIV-infected adults with tuberculosis?
Conclusion
Early cART reduced mortality among individuals with low CD4 counts and improved retention in care, regardless of CD4 count.
Supporting Evidence
- Early cART initiation led to a survival benefit that was most marked for individuals with low CD4 counts.
- cART initiation at day 15 yielded 2-y survival probabilities of 0.82 and 0.86 for individuals with CD4 counts of 50 and 100 cells/µl, respectively.
- Results were similar for the endpoint of death, hospitalization, or serious opportunistic infection.
Takeaway
Starting HIV treatment early helps people with tuberculosis live longer and stay in care better.
Methodology
Retrospective review of patient charts to estimate the effect of cART on survival using marginal structural models.
Potential Biases
Potential biases from residual confounding and model misspecification.
Limitations
The study's observational nature may introduce biases from unmeasured confounding factors.
Participant Demographics
HIV-infected adults aged 15 years or older with CD4 counts ≤350 cells/µl diagnosed with TB.
Statistical Information
P-Value
0.03
Confidence Interval
[0.76, 0.89]
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website